Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) to AstraZeneca is fair to Fusion shareholders. Under the terms of the proposed transaction, AstraZeneca would acquire all of Fusion’s outstanding shares for $21.00 per share in cash at closing plus a non-transferable contingent value right of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone.

Halper Sadeh encourages Fusion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

The investigation concerns whether Fusion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Fusion shareholders; (2) determine whether AstraZeneca is underpaying for Fusion; and (3) disclose all material information necessary for Fusion shareholders to adequately assess and value the merger consideration.

On behalf of Fusion shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240319065505/en/